348 related articles for article (PubMed ID: 25303979)
1. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
Yu HA; Riely GJ; Lovly CM
Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
[TBL] [Abstract][Full Text] [Related]
2. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Gao J; Li HR; Jin C; Jiang JH; Ding JY
Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
[TBL] [Abstract][Full Text] [Related]
3. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
4. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
[TBL] [Abstract][Full Text] [Related]
6. EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
[TBL] [Abstract][Full Text] [Related]
7. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
Liao BC; Lin CC; Lee JH; Yang JC
J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760
[TBL] [Abstract][Full Text] [Related]
8. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.
Suda K; Rivard CJ; Mitsudomi T; Hirsch FR
Expert Rev Anticancer Ther; 2017 Sep; 17(9):779-786. PubMed ID: 28701107
[TBL] [Abstract][Full Text] [Related]
10. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
11. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
12. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
13. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
Ni L; Nie L
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
17. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
[TBL] [Abstract][Full Text] [Related]
18. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.
Husain H; Scur M; Murtuza A; Bui N; Woodward B; Kurzrock R
Mol Cancer Ther; 2017 Feb; 16(2):265-272. PubMed ID: 28159915
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
Wang S; Song Y; Yan F; Liu D
Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Westover D; Zugazagoitia J; Cho BC; Lovly CM; Paz-Ares L
Ann Oncol; 2018 Jan; 29(suppl_1):i10-i19. PubMed ID: 29462254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
